Ikarovec is a company that develops treatments for complex diseases. The company focuses on producing treatments that they describe as elegant.

ikarovec 

Ikarovec

The company has an early stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms) and ocular hypertension. 

Future Planet Capital

LifeArc

UK Innovation & Science Seed Fund

Parkwalk Advisors

Will I see you in Boston? 👀

📣 I am excited to be speaking at the 5th Gene Therapy for Ophthalmic Disorders Summit this September 10-12 in Boston, MA! 

💡 On Day 2 I will be presenting 'Insights from Preclinical Disease Modelling in Ophthalmic Gene Therapy' and showcasing the phenomenal amount of work produced by the research team at ikarovec 

Here’s the link: https://ter.li/xs2c2a 

👋 Feel free to reach out to introduce yourself or to arrange a catch-up!  ☕ 

#ikarovec #genetherapy #ophthalmology #fightingblindness

🔬 After a short leave of absence ikarovec image of the month has returned!
 
😎 Over August, we will be dialling back our LinkedIn activities for a well earned rest.

👀 But keep your eyes peeled in September for a big announcement…📣

#genetherapy #biotechstartup #AMD #ophthalmology #microscopy #H&E #summerholidays

Ikarovec’s CSO Katie Binley took part in the One Nucleus On Helix panel discussion today all about the Boston Bootcamp. 

It was a great opportunity for the panel to share learnings, challenges and opportunities from the experience with the Cambridge UK life sciences ecosystem.

This week ikarovec  CSO Katie Binley was thrilled to be selected to give a presentation at the British Society for Gene and Cell Therapy (BSGCT) in the CNS & Ocular session chaired by Carly Bliss & @Michelle McClements. 

It was a honour to speak alongside Simon Waddington (development of a much needed gene therapy to treat dopamine transporter deficiency , hDAT) Jasmina Cehajic Kapetanovic (clinical gene therapies for inherited retinal diseases including RPGR, optogenetics and robotic assisted surgery), @Ralph Hector (a self regulating gene therapy for Rett Syndrome) and @Katie Greed who gave a passionate and personal presentation of living with Phelon McDermid Syndrome (PMS)

📣 Katie Binley, ikarovec’s Chief Scientific Officer, will give an oral presentation on Tuesday 18th June at the Annual British Society for Gene and Cell Therapy (BSGCT) in Oxford at the Saïd Business School, University of Oxford. 

The talk will focus on the exciting scientific achievements at ikarovec from the design of a next generation bicistronic AAV-based gene therapy to treat geographic atrophy through to the demonstration of robust efficacy in key proof-of-concept ocular models.   

#genetherapy  #AMD #ophthalmology

Ikarovec is excited to be part of the Cell and Gene Therapy Catapult Consortium, partnering with Croda and UCL, to advance the development of formulation buffers for their lead AAV vector targeting GA.

 🔍 💡 🔬

IKAR

COM:IKAROVEC

Ikarovec

locale

market

industry

website

linkedin

founding date

investor of

Metrics